Renova’s 50% DMSO Is a Prescription Bladder Treatment

Renova’s DMSO Irrigation, 50%, is a sterile prescription solution placed inside the bladder for symptomatic relief of interstitial cystitis. It is not an MSM supplement, a skin-care product or a general-purpose pain treatment. The product’s labeling specifies intravesical administration—into the bladder—and explicitly rules out intramuscular and intravenous injection. Renova prescribing information

For anyone finding this product through an online DMSO search, the important distinction is the approved formulation, route and condition, not simply the letters “DMSO” or the percentage on the bottle.

What launched, and when?

ROI-NJ reported on September 14, 2026, that Renova had announced the commercial launch of its first three U.S. generic products on September 11, including DMSO Irrigation, 50%. The other two were L-glutamine for oral solution and ascorbic acid injection. Launch report

As of October 24, 2026, FDA’s Competitive Generic Therapy approval list independently identifies the relevant application, ANDA 220173, as approved on July 7, 2026, with first commercial marketing on September 11. It names Stira Pharmaceuticals LLC as the applicant and RIMSO-50 as the reference listed drug. Renova’s label carries the same application number and identifies Renova as the distributor and Stira as the manufacturer. These are different roles associated with the same product. FDA approval record; product labeling

The Competitive Generic Therapy designation concerns encouraging competition where generic competition is inadequate. It is not a new indication or evidence that DMSO treats additional diseases. FDA explanation

What “50%” and “irrigation” mean

Renova’s labeling provides these identifying details:

Label detail	Meaning
Dimethyl Sulfoxide Irrigation, USP 50% w/w	The concentration is 50% by weight, not by volume.
Aqueous solution	Water is the inactive ingredient.
Sterile and non-pyrogenic	These are stated properties of this prescription preparation.
50 mL glass vial	The listed package size.
NDC 84897-052-01	The package identifier a clinic or pharmacy can use to check the product.

The label also states that each milliliter contains 0.54 grams of DMSO. “50%” describes concentration; “50 mL” describes vial volume. They are not the same measurement. Renova product labeling

Here, “irrigation” refers to a solution used for bladder instillation, not something to drink or apply to the skin. The prescribing information describes administration through a catheter or an asepto syringe, with treatment managed by a physician. It is not a home dilution recipe. Prescribing information

What the approval does—and does not—support

The labeled indication is symptomatic relief in patients with interstitial cystitis. That is narrower than a claim to cure the condition. The label also says there is no clinical evidence of effectiveness against bacterial urinary tract infections and that the product has not been approved as safe and effective for other indications. Prescribing information

The commercial launch adds a generic product; it does not itself provide a new clinical trial demonstrating better symptom relief. Nor does bladder-treatment approval establish that DMSO creams, roll-ons or industrial solvents work for joint pain, wrinkles or other uses. Our guide to established DMSO uses versus health claims explains that distinction.

Safety questions belong with the treating clinician

The Renova label describes several treatment-specific risks and precautions:

• Discomfort and bladder irritation: Moderately severe discomfort can occur during administration, and transient chemical cystitis has been reported.
• Taste and odor: A garlic-like taste may last several hours; breath and skin odor may persist for up to 72 hours.
• Hypersensitivity and medication effects: Hypersensitivity reactions are possible, and DMSO may increase the effects of other medicines.
• Monitoring: The label recommends eye evaluations before and periodically during treatment because lens changes occurred in animals given high doses chronically. It also recommends approximately six-monthly blood counts and biochemical screening, particularly liver and kidney function tests.
• Special circumstances: The label warns that bladder instillation may be harmful in patients with urinary tract malignancy. Use during pregnancy requires weighing potential benefit against fetal risk; caution is advised during breastfeeding. Safety and effectiveness in children have not been established.

These precautions come from the product’s prescribing information, not from general advice about topical DMSO.

Do not substitute retail DMSO or MSM

A retail bottle labeled “50% DMSO” does not establish that it matches this sterile prescription bladder preparation. Memorial Sloan Kettering distinguishes approved intravesical DMSO from unapproved over-the-counter use and warns that industrial DMSO may contain other chemicals. MSK DMSO safety overview

MSM—methylsulfonylmethane—is a chemically related but different substance sold as a dietary supplement, not a replacement for prescribed DMSO. NCCIH overview Likewise, dilution math cannot establish sterility, suitability or an approved medical use.

If your urologist proposes Renova’s product, ask the clinic or dispensing pharmacy to confirm the exact formulation and NDC, review your full medication list, and explain the administration plan and monitoring. For cost, request both the medication charge and any procedure charges; the launch report provides no retail price or patient-specific coverage information.